Bendamustine Liquid Formulations for Long-Term Impurity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bendamustine free base exhibits rapid degradation upon reconstitution, leading to the formation of impurities such as HP1 and HP2, which complicates its stability and suitability for long-term storage in liquid form.
Innovation Solution
The development of bendamustine-containing compositions that include a pharmaceutically acceptable fluid such as propylene glycol, polyethylene glycol, or DMSO, combined with a stabilizing amount of a chloride salt or antioxidant, to enhance the stability and reduce impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If bendamustine is stored in liquid form after reconstitution, then it becomes ready for immediate use, but it degrades rapidly forming impurities HP1 and HP2
Solution Approach 1:
The patent introduces specific excipients as intermediary substances that mediate between bendamustine and the degradation process. These include: (1) Chloride salts (sodium chloride, potassium chloride, calcium chloride, magnesium chloride) that stabilize bendamustine against hydrolysis; (2) Antioxidants (ascorbic acid, sodium ascorbate, vitamin E) that prevent oxidation; (3) pH buffers (citric acid, sodium citrate, phosphoric acid, sodium phosphate) that maintain stable pH levels. These intermediaries collectively prevent the formation of degradants HP1 and HP2 while maintaining readiness for use.
Solution Approach 2:
The patent employs parameter changes to control the stability of bendamustine in liquid formulation. Specifically: (1) pH control by buffers to maintain optimal pH range; (2) Concentration optimization of bendamustine (typically 1-10 mg/mL); (3) Temperature control during storage and administration; (4) Excipient concentration levels that provide adequate protection against degradation. These parameter adjustments enable long-term stability while maintaining immediate usability.
2Productivity
If bendamustine is reconstituted from lyophilized powder, then it achieves liquid formulation for administration, but it takes 15-30 minutes and exhibits chemical instability
Solution Approach 1:
The patent applies preliminary action by pre-formulating bendamustine in stable liquid or concentrated liquid form before administration, eliminating the need for on-site reconstitution. The formulation includes pre-added stabilizing excipients (chloride salts, antioxidants, buffers) that prevent degradation during storage and administration, reducing preparation time to essentially zero while maintaining chemical stability.
Solution Approach 2:
The patent changes the physical state parameter from solid lyophilized powder to liquid or concentrated liquid formulation, enabling direct administration without reconstitution. This parameter change, combined with optimized concentration levels and stabilizing excipients, achieves immediate usability while preventing the 15-30 minute reconstitution time and associated instability.
3Stability of the object's composition
If bendamustine is formulated with stabilizing excipients, then long-term stability is improved, but the formulation complexity increases
Solution Approach 1:
The patent merges multiple stabilizing functions into a single integrated formulation system. Instead of using separate protection mechanisms, the formulation combines chloride salts, antioxidants, and pH buffers in a unified liquid or concentrated liquid formulation. This merging approach achieves comprehensive stability protection against multiple degradation pathways (hydrolysis, oxidation, pH-related degradation) while maintaining a single simple formulation structure that is straightforward to prepare and administer.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions demonstrate significantly improved long-term stability, with total impurities less than 5% after at least 15 months at temperatures ranging from 5°C to 25°C, making them suitable for extended storage and use.
Implementation Method 1
Bendamustine undergoes hydrolysis by direct substitution rather than an addition elimination process due to the presence of the highly labile aliphatic chlorine atoms
Implementation Method 2
a pharmaceutically acceptable fluid which contains one or more of propylene glycol, ethanol, polyethylene glycol, benzyl alcohol and glycofurol
Data Source
AI summary
Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.